卒中后90天药物依从性的种族差异
基于脑卒中监测项目,纳入2008至2015年缺血性卒中患者,随访3个月评估5类药物依从性。墨西哥裔美国人(n=692)与非西班牙裔白人(n=422)在5类药物的依从性上均无显著差异,挑战了依从性作为卒中复发差异解释的观点。
要点
- 墨西哥裔美国人与非西班牙裔白人卒中后3个月5类药物的依从性无显著差异。
- 依从性定义为典型一周内报告从未漏服药物。
- 卒中复发差异可能需从提供者和卫生系统因素探索。
核心结论
- 本研究未发现墨西哥裔美国人与非西班牙裔白人之间卒中后3个月药物依从性的种族差异,因此对依从性作为卒中复发差异解释提出挑战。
研究设计与样本
- 基于人群的前瞻性研究,纳入2008至2015年德克萨斯州Corpus Christi项目中的缺血性卒中病例,随访3个月评估药物依从性。
- 墨西哥裔美国人n=692,非西班牙裔白人n=422,分析5类药物的依从性。
主要发现
- 墨西哥裔美国人较非西班牙裔白人更年轻(中位65岁 vs 68岁,P<0.001),糖尿病(P<0.001)和高血压(P<0.001)更多,心房颤动(P=0.003)、吸烟(P=0.003)和教育程度(P<0.001)更低。
- 5类药物(他汀类、抗血小板药、抗凝药、抗高血压药、抗抑郁药)的依从性在两组间均无显著差异。
关键数值与推荐
- 依从性定义为患者报告在典型一周内从未漏服药物。
- 使用χ2检验或Kruskal-Wallis非参数检验进行种族比较,并构建多变量逻辑回归模型分析种族与药物不依从性的关联。
临床怎么用
- 临床实践中应关注卒中后药物依从性,但依从性可能不是墨西哥裔美国人卒中复发风险增高的主要原因。
- 需进一步探索提供者和卫生系统因素以解释卒中复发差异。
局限性
- 依从性基于患者自我报告,可能存在回忆偏倚。
- 研究仅纳入德克萨斯州Corpus Christi地区的缺血性卒中患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- We assessed ethnic differences in medication adherence 3 months poststroke in a population-based study as an initial step in investigating the increased stroke recurrence risk in Mexican Americans compared with non-Hispanic whites. Methods- Ischemic stroke cases from 2008 to 2015 from the Brain Attack Surveillance in Corpus Christi project in Texas were followed prospectively for 3 months poststroke to assess medication adherence. Medications in 5 drug classes were analyzed: statins, antiplatelets, anticoagulants, antihypertensives, and antidepressants. For each drug class, patients were considered adherent if they reported never missing a dose in a typical week. The χ2 tests or Kruskal-Wallis nonparametric tests were used for ethnic comparisons of demographics, risk factors, and medication adherence. A multivariable logistic regression model was constructed for the association of ethnicity and medication nonadherence. Results- Mexican Americans (n=692) were younger (median 65 years versus 68 years, P<0.001), had more diabetes mellitus ( P<0.001) and hypertension ( P<0.001) and less atrial fibrillation ( P=0.003), smoking ( P=0.003), and education ( P<0.001) than non-Hispanic whites (n=422). Sex, insurance status, high cholesterol, previous stroke/transient ischemic attack history, excessive alcohol use, tPA (tissue-type plasminogen activator) treatment, National Institutes of Health Stroke Scale score, and comorbidity index did not significantly differ by ethnicity. There was no significant difference in medication adherence for any of the 5 drug classes between Mexican Americans and non-Hispanic whites. Conclusions- This study did not find ethnic differences in medication adherence, thus challenging this patient-level factor as an explanation for stroke recurrence disparities. Other reasons for the excessive stroke recurrence burden in Mexican Americans, including provider and health system factors, should be explored.
引用
- Lank RJ, Lisabeth LD, Levine DA, et al. Ethnic Differences in 90-Day Poststroke Medication Adherence. Stroke. 2019. PMID: 31084331. doi:10.1161/STROKEAHA.118.024249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。